Maxygen receives $14.4 million of grants, contract for HIV vaccine research

New York, Oct. 20 - Maxygen, Inc. said it has been awarded grants and a contract totaling $14.4 million from the National Institutes of Health and the U.S. Department of Defense for research on a preventative HIV vaccine.

Specifically, the National Institutes of Health awarded Maxygen two competitive grants including $11.7 million over five years as part of the HIV Research and Development program and a phase I grant from the National Institutes of Health Small Business Innovation Research program.

Maxygen was also awarded a contract of $2.4 million from the Department of Defense for HIV vaccine discovery.

The HIV Research and Development grant provides funds for the use of Maxygen's MolecularBreeding directed evolution platform to generate novel HIV-1 antigens potentially capable of inducing broad antibody responses to multiple strains of the HIV-1 virus.

The Small Business Innovation Research award will fund investigations into the effect on immunogenicity of secondary modifications to a specific HIV-1 envelope protein.

The contract from the Department of Defense will fund work to develop a high-throughput vaccine screening platform.

Redwood City, Calif.-based Maxygen anticipates collaborating with Monogram Biosciences and Aldevron LLC on the projects.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.